Myeloablative regimens: incidence of nonrelapse mortality, relapse, and disease-free and overall survival. (A) Relapse. The 1-year cumulative incidence of relapse was 19% (95% CI, 17-22) for Haplo relative donor (a) and 21% (95% CI, 23-41) for MUD (b) transplants. (B) Nonrelapse mortality. The 1-year cumulative incidence of nonrelapse mortality was 15% (95% CI, 13-18) for Haplo relative donor (a) and 15% (95% CI, 8-23) for MUD (b) transplants. (C) Overall survival. The 1-year probability of overall survival was 75% (95% CI, 72-78) for Haplo relative donor (a) and 77% (95% CI, 68-85) for MUD (b) transplants. (D) Disease-free survival. The 1-year probability of disease-free survival was 66% (95% CI, 62-69) for Haplo relative donor (a) and 65% (95% CI, 54-74) for MUD (b) transplants.